Key result
Cardioversion and standard pharmacotherapy are safe and effective for acute PSVT during pregnancy.
Why the study?
The safety and efficacy of pharmacologic agents and cardioversion for treating paroxysmal supraventricular tachycardia in pregnancy require clarification to guide management.
Are standard pharmacologic agents and synchronized direct-current cardioversion safe and effective for treating acute paroxysmal supraventricular tachycardia in pregnancy?
Are standard pharmacologic agents and synchronized direct-current cardioversion safe and effective for treating acute paroxysmal supraventricular tachycardia in pregnancy?
Standard pharmacologic therapies and synchronized direct-current cardioversion are safe and effective for managing acute PSVT in pregnant patients.
May support standard PSVT therapies in pregnancy; leaves open need for prospective trials before practice change.
The treatment of paroxysmal supraventricular tachycardia (PSVT) in pregnancy is not unlike treatment for the general population.The physician should feel confident that the pharmacologic agents ordinarily used to treat this common problem in the general population are safe for both mother and fetus when administered under monitored conditions.In treating paroxysmal supraventricular tachycardia in pregnancy, when both vagal maneuvers and exhaustive medical therapy fail, synchronized, direct-current cardioversion is a safe and effective form of treatment.
No takes yet. Share an insight, caveat, or question.
Parlow et al. (1991) conducted a review in Acute paroxysmal supraventricular tachycardia in pregnancy. Pharmacologic agents and synchronized direct-current cardioversion was evaluated. Pharmacologic agents and synchronized direct-current cardioversion are safe and effective for treating acute paroxysmal supraventricular tachycardia during pregnancy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: